Your browser doesn't support javascript.
loading
Neoadjuvant PD-1 Immune Checkpoint Blockade Reverses Functional Immunodominance among Tumor Antigen-Specific T Cells.
Friedman, Jay; Moore, Ellen C; Zolkind, Paul; Robbins, Yvette; Clavijo, Paul E; Sun, Lilian; Greene, Sarah; Morisada, Megan V; Mydlarz, Wojciech K; Schmitt, Nicole; Hodge, James W; Schreiber, Hans; Van Waes, Carter; Uppaluri, Ravindra; Allen, Clint.
Afiliação
  • Friedman J; Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.
  • Moore EC; Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.
  • Zolkind P; Department of Otolaryngology-Head and Neck Surgery, Washington University in St. Louis, St. Louis, Missouri.
  • Robbins Y; Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.
  • Clavijo PE; Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.
  • Sun L; Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.
  • Greene S; Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.
  • Morisada MV; Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.
  • Mydlarz WK; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Schmitt N; Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland.
  • Hodge JW; Laboratory of Tumor Immunology and Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
  • Schreiber H; Department of Pathology, University of Chicago, Chicago, Illinois.
  • Van Waes C; Tumor Biology Section, Head and Neck Surgery Branch, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland.
  • Uppaluri R; Department of Surgery/Otolaryngology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Allen C; Translational Tumor Immunology Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health, Bethesda, Maryland. clint.allen@nih.gov.
Clin Cancer Res ; 26(3): 679-689, 2020 02 01.
Article em En | MEDLINE | ID: mdl-31645352
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Boca Base de dados: MEDLINE Assunto principal: Neoplasias Bucais / Linfócitos T / Epitopos Imunodominantes / Terapia Neoadjuvante / Receptor de Morte Celular Programada 1 / Anticorpos Monoclonais Limite: Animals / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Boca Base de dados: MEDLINE Assunto principal: Neoplasias Bucais / Linfócitos T / Epitopos Imunodominantes / Terapia Neoadjuvante / Receptor de Morte Celular Programada 1 / Anticorpos Monoclonais Limite: Animals / Humans Idioma: En Revista: Clin Cancer Res Assunto da revista: NEOPLASIAS Ano de publicação: 2020 Tipo de documento: Article